Archive | Onglyza RSS feed for this section

Onglyza Linked to Pancreatic Cancer

10. September 2015

Comments Off on Onglyza Linked to Pancreatic Cancer

The popular diabetes type-2 treatment Onglyza (saxagliptin) was jointly developed by AstraZeneca and Bristol-Myers Squibb. Onglyza is a popular medication, partly because it effectively controls blood sugar and does not encourage weight gain like other diabetes medications. The FDA has already recognized the link between Onglyza and a different health threat, heart failure. In April […]

Continue reading...